サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1611190

女性の健康の世界市場規模、シェア、動向分析レポート：用途別、薬剤クラス別、年齢別、地域別、セグメント別予測（2025年～2030年）

Women's Health Market Size, Share & Trends Analysis Report By Application (Contraceptives, Menopause), By Drug Class (Hormonal Therapies, Pain And Symptom Management), By Age (50 Years And Above), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 130 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.08円
女性の健康の世界市場規模、シェア、動向分析レポート：用途別、薬剤クラス別、年齢別、地域別、セグメント別予測（2025年～2030年）
出版日: 2024年11月22日
発行: Grand View Research
ページ情報: 英文 130 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

女性の健康市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の女性の健康の市場規模は、2025～2030年にCAGR5.1％を記録し、2030年には685億3,000万米ドルに達する見込みです。

革新的な新製品の導入と、女性の健康に関する強力なパイプラインの存在が、市場成長を促進する主な要因です。例えば、2021年5月に食品医薬品局は、ファイザーがミオバントサイエンシズと共同開発した、月経多量出血に伴う子宮筋腫のためのマイフェンブリーを承認しました。子宮内膜症の罹患率の増加と非営利団体からの支援の増加は、予測期間中の市場成長を促進すると予想されます。

例えば、ビル＆メリンダ・ゲイツ財団は、新しい避妊技術の開発と家族計画イニシアチブを支援するために、2021～2030年まで毎年2億8,000万米ドルを拠出することを約束しました。WHOの報告書2021年によると、世界では生殖年齢にある少女と女性の約10％（1億9,000万人）が子宮内膜症に罹患しています。子宮内膜症は、生理痛、排便痛、腹部膨満感、吐き気、疲労感などを伴う慢性疾患です。COVID-19の大流行は市場に悪影響を与えました。SARS-CoV-2の蔓延を抑制するために政府が実施した、ソーシャルディスタンス措置や地域全体のロックダウンのような厳しい措置は、治療施設や婦人科クリニックに悪影響を与えました。

例えば、低・中所得国では、長時間・短時間作用型の可逆的避妊薬の使用が減少しています。製品の開発と商業化のために、主要企業が共同研究、契約、提携などの戦略的な取り組みを行うことは、市場の成長を促進すると予想されます。例えば、2021年10月、リヒターとヒクマは、XgevaとProliaのバイオシミラーを構成するデノスマブを米国で商業化するための独占的ライセンス契約を締結しました。さらに、ジェネリック医薬品との競争激化は、特許満了後の価格圧力を高め、市場成長を抑制すると予想されます。

例えば、特許失効後のフォルテオの売上は、2020～2021年に23%減少しました。2021年の世界市場は、有利な償還政策、主要市場企業の存在、政府による支持的な規制、製品の承認と商業化、女性の避妊具使用率の高さなどにより、北米が優位を占めました。アジア太平洋は、女性の健康に対する政府支出の増加により、予測期間中に最も速いCAGRで成長すると予想されます。例えば、オーストラリア政府は保健サービスとサポートを支援するために3億3,300万米ドルの投資を発表しました。

女性の健康市場レポートのハイライト

  • 避妊薬セグメントは、家族計画に対する意識の高まりと避妊法の技術的進歩の継続によって拍車がかかり、2024年の世界収益の35.07％以上という最も高い収益シェアを占めました。
  • ホルモン療法セグメントは2024年に市場をリードし、予測期間中に最も速い成長率が見込まれます。
  • その他（50歳未満）セグメントは2024年に市場を独占し、予測期間中もその地位を維持すると予想されます。50歳未満の女性は、子宮内膜症、ホルモン性不妊症、多嚢胞性卵巣症候群など、不妊に関連する問題に直面する可能性が高いです。
  • 北米の女性の健康市場は、2024年に43.04％のシェアで世界市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 女性の健康市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 女性の健康市場分析ツール
    • 業界分析：ポーターのファイブフォース分析
    • PESTEL分析
    • 価格分析

第4章 女性の健康市場：用途の推定・動向分析

  • 用途の市場シェア（2024年・2030年）
  • セグメントダッシュボード
  • 世界の女性の健康市場：用途の展望
  • 2018～2030年の市場規模と予測および動向分析
    • ホルモン性不妊症
    • 避妊薬
    • 閉経後骨粗鬆症
    • 子宮内膜症と子宮筋腫
    • 閉経
    • 多嚢胞性卵巣症候群（PCOS）

第5章 女性の健康市場：薬剤クラスの推定・動向分析

  • 薬物クラスの市場シェア（2024年・2030年）
  • セグメントダッシュボード
  • 世界の女性の健康市場：薬剤クラスの展望
  • 2018～2030年の市場規模と予測および動向分析
    • ホルモン療法
    • 骨の健康促進剤
    • 不妊治療薬
    • GnRHモジュレーター
    • 痛みと症状の管理
    • 代謝剤
    • その他

第6章 女性の健康市場：年齢の推定・動向分析

  • 年齢の市場シェア（2024年・2030年）
  • セグメントダッシュボード
  • 世界の女性の健康市場：年齢の展望
  • 2018～2030年の市場規模と予測および動向分析
    • 50歳以上
    • その他

第7章 女性の健康市場：地域の推定・動向分析

  • 地域別市場シェア分析（2024年・2030年）
  • 地域市場ダッシュボード
  • 世界の地域市場のスナップショット
  • 市場規模と予測動向分析（2018～2030年）
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要販売代理店およびチャネルパートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析：2024年
    • AbbVie, Inc.
    • Bayer AG
    • Merck &Co., Inc.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Agile Therapeutics
    • Amgen, Inc.
    • Apothecus Pharmaceutical Corp.
    • Blairex Laboratories, Inc.
    • Ferring BV
図表

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America women's health market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America women's health market, by application, 2018 - 2030 (USD Million)
  • Table 4 North America women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 5 North America women's health market, by age, 2018 - 2030 (USD Million)
  • Table 6 U.S. women's health market, by application, 2018 - 2030 (USD Million)
  • Table 7 U.S. women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 8 U.S. women's health market, by age, 2018 - 2030 (USD Million)
  • Table 9 Canada women's health market, by application, 2018 - 2030 (USD Million)
  • Table 10 Canada women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 11 Canada women's health market, by age, 2018 - 2030 (USD Million)
  • Table 12 Mexico women's health market, by application, 2018 - 2030 (USD Million)
  • Table 13 Mexico women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 14 Mexico women's health market, by age, 2018 - 2030 (USD Million)
  • Table 15 Europe women's health market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe women's health market, by application, 2018 - 2030 (USD Million)
  • Table 17 Europe women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 18 Europe women's health market, by age, 2018 - 2030 (USD Million)
  • Table 19 Germany women's health market, by application, 2018 - 2030 (USD Million)
  • Table 20 Germany women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 21 Germany women's health market, by age, 2018 - 2030 (USD Million)
  • Table 22 UK women's health market, by application, 2018 - 2030 (USD Million)
  • Table 23 UK women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 24 UK women's health market, by age, 2018 - 2030 (USD Million)
  • Table 25 France women's health market, by application, 2018 - 2030 (USD Million)
  • Table 26 France women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 27 France women's health market, by age, 2018 - 2030 (USD Million)
  • Table 28 Italy women's health market, by application, 2018 - 2030 (USD Million)
  • Table 29 Italy women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 30 Italy women's health market, by age, 2018 - 2030 (USD Million)
  • Table 31 Spain women's health market, by application, 2018 - 2030 (USD Million)
  • Table 32 Spain women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 33 Spain women's health market, by age, 2018 - 2030 (USD Million)
  • Table 34 Denmark women's health market, by application, 2018 - 2030 (USD Million)
  • Table 35 Denmark women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 36 Denmark women's health market, by age, 2018 - 2030 (USD Million)
  • Table 37 Sweden women's health market, by application, 2018 - 2030 (USD Million)
  • Table 38 Sweden women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 39 Sweden women's health market, by age, 2018 - 2030 (USD Million)
  • Table 40 Norway women's health market, by application, 2018 - 2030 (USD Million)
  • Table 41 Norway women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 42 Norway women's health market, by age, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific women's health market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific women's health market, by application, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific women's health market, by age, 2018 - 2030 (USD Million)
  • Table 47 China women's health market, by application, 2018 - 2030 (USD Million)
  • Table 48 China women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 49 China women's health market, by age, 2018 - 2030 (USD Million)
  • Table 50 Japan women's health market, by application, 2018 - 2030 (USD Million)
  • Table 51 Japan women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 52 Japan women's health market, by age, 2018 - 2030 (USD Million)
  • Table 53 India women's health market, by application, 2018 - 2030 (USD Million)
  • Table 54 India women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 55 India women's health market, by age, 2018 - 2030 (USD Million)
  • Table 56 South Korea women's health market, by application, 2018 - 2030 (USD Million)
  • Table 57 South Korea women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 58 South Korea women's health market, by age, 2018 - 2030 (USD Million)
  • Table 59 Australia women's health market, by application, 2018 - 2030 (USD Million)
  • Table 60 Australia women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 61 Australia women's health market, by age, 2018 - 2030 (USD Million)
  • Table 62 Thailand women's health market, by application, 2018 - 2030 (USD Million)
  • Table 63 Thailand women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 64 Thailand women's health market, by age, 2018 - 2030 (USD Million)
  • Table 65 Latin America women's health market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America women's health market, by age, 2018 - 2030 (USD Million)
  • Table 67 Latin America women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 68 Latin America women's health market, by application, 2018 - 2030 (USD Million)
  • Table 69 Brazil women's health market, by application, 2018 - 2030 (USD Million)
  • Table 70 Brazil women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 71 Brazil women's health market, by age, 2018 - 2030 (USD Million)
  • Table 72 Argentina women's health market, by application, 2018 - 2030 (USD Million)
  • Table 73 Argentina women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 74 Argentina women's health market, by age, 2018 - 2030 (USD Million)
  • Table 75 MEA women's health market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA women's health market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 78 MEA women's health market, by age, 2018 - 2030 (USD Million)
  • Table 79 South Africa women's health market, by application, 2018 - 2030 (USD Million)
  • Table 80 South Africa women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 81 South Africa women's health market, by age, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia women's health market, by application, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia women's health market, by age, 2018 - 2030 (USD Million)
  • Table 85 UAE women's health market, by application, 2018 - 2030 (USD Million)
  • Table 86 UAE women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 87 UAE women's health market, by age, 2018 - 2030 (USD Million)
  • Table 88 Kuwait women's health market, by application, 2018 - 2030 (USD Million)
  • Table 89 Kuwait women's health market, by drug class, 2018 - 2030 (USD Million)
  • Table 90 Kuwait women's health market, by age, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Women's health market: market outlook
  • Fig. 14 Women's health competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Women's health market driver impact
  • Fig. 20 Women's health market restraint impact
  • Fig. 21 Women's health market strategic initiatives analysis
  • Fig. 22 Women's health market: Application movement analysis
  • Fig. 23 Women's health market: Application outlook and key takeaways
  • Fig. 24 Hormonal infertility market estimates and forecast, 2018 - 2030
  • Fig. 25 Contraceptives estimates and forecast, 2018 - 2030
  • Fig. 26 Postmenopausal osteoporosis market estimates and forecast, 2018 - 2030
  • Fig. 27 Endometriosis & uterine fibroids estimates and forecast, 2018 - 2030
  • Fig. 28 Menopause market estimates and forecast, 2018 - 2030
  • Fig. 29 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018 - 2030
  • Fig. 30 Women's health market: Drug movement analysis
  • Fig. 31 Women's health market: Drug outlook and key takeaways
  • Fig. 32 Hormonal Therapies market estimates and forecast, 2018 - 2030
  • Fig. 33 Bone Health Agents market estimates and forecast, 2018 - 2030
  • Fig. 34 Fertility Agents market estimates and forecast, 2018 - 2030
  • Fig. 35 GnRH Modulators estimates and forecast, 2018 - 2030
  • Fig. 36 Pain and Symptom Management market estimates and forecast, 2018 - 2030
  • Fig. 37 Metabolic Agents estimates and forecast, 2018 - 2030
  • Fig. 38 Others estimates and forecast, 2018 - 2030
  • Fig. 39 Women's health Market: Age movement Analysis
  • Fig. 40 Women's health market: Age outlook and key takeaways
  • Fig. 41 50 years and above market estimates and forecasts, 2018 - 2030
  • Fig. 42 Postmenopausal osteoporosis market estimates and forecasts,2018 - 2030
  • Fig. 43 Endometriosis & uterine fibroids market estimates and forecasts,2018 - 2030
  • Fig. 44 Menopause market estimates and forecasts,2018 - 2030
  • Fig. 45 Others market estimates and forecasts,2018 - 2030
  • Fig. 46 Others market estimates and forecasts,2018 - 2030
  • Fig. 47 Global women's health market: Regional movement analysis
  • Fig. 48 Global women's health market: Regional outlook and key takeaways
  • Fig. 49 Global women's health market share and leading players
  • Fig. 50 North America market share and leading players
  • Fig. 51 Europe market share and leading players
  • Fig. 52 Asia Pacific market share and leading players
  • Fig. 53 Latin America market share and leading players
  • Fig. 54 Middle East & Africa market share and leading players
  • Fig. 55 North America: SWOT
  • Fig. 56 Europe SWOT
  • Fig. 57 Asia Pacific SWOT
  • Fig. 58 Latin America SWOT
  • Fig. 59 MEA SWOT
  • Fig. 60 North America, by country
  • Fig. 61 North America
  • Fig. 62 North America market estimates and forecasts, 2018 - 2030
  • Fig. 63 U.S.
  • Fig. 64 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 65 Canada
  • Fig. 66 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 67 Mexico
  • Fig. 68 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 69 Europe
  • Fig. 70 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 71 UK
  • Fig. 72 UK market estimates and forecasts, 2018 - 2030
  • Fig. 73 Germany
  • Fig. 74 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 75 France
  • Fig. 76 France market estimates and forecasts, 2018 - 2030
  • Fig. 77 Italy
  • Fig. 78 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 79 Spain
  • Fig. 80 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 81 Denmark
  • Fig. 82 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 83 Sweden
  • Fig. 84 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 85 Norway
  • Fig. 86 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 87 Asia Pacific
  • Fig. 88 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 89 China
  • Fig. 90 China market estimates and forecasts, 2018 - 2030
  • Fig. 91 Japan
  • Fig. 92 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 93 India
  • Fig. 94 India market estimates and forecasts, 2018 - 2030
  • Fig. 95 Thailand
  • Fig. 96 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 97 South Korea
  • Fig. 98 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 99 Australia
  • Fig. 100 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 101 Latin America
  • Fig. 102 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 103 Brazil
  • Fig. 104 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 105 Argentina
  • Fig. 106 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 107 Middle East and Africa
  • Fig. 108 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 109 South Africa
  • Fig. 110 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 111 Saudi Arabia
  • Fig. 112 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 113 UAE
  • Fig. 114 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 115 Kuwait
  • Fig. 116 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 117 Market share of key market players- Women's health market
目次
Product Code: GVR-1-68038-634-9

Women's Health Market Growth & Trends:

The global women's health market size is expected to reach USD 68.53 billion by 2030, registering a CAGR of 5.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The introduction of innovative novel products and the presence of a strong pipeline of women's health products are prime factors driving the market growth. For instance, in May 2021, the Food & Drug Administration approved Myfembree, developed by Pfizer Inc. in collaboration with Myovant Sciences, for uterine fibroids associated with heavy menstrual bleeding. An increase in the incidence of endometriosis and a rise in support from non-profit organizations are expected to fuel the market growth over the forecast period.

For instance, the Bill & Melinda Gates Foundation pledged USD 280 million every year from 2021 to 2030 for the development of new contraceptive technologies and to support family planning initiatives. According to the WHO report 2021, globally, around 10% (190 million) of reproductive-age girls and women are affected by endometriosis. It is a chronic disease related to severe pain during periods, bowel movements and/or urination, abdominal bloating, nausea, fatigue, etc. The COVID-19 pandemic had a negative impact on the market. Strict measures undertaken by governments to control the spread of the SARS-CoV-2, such as social distancing and community-wide lockdowns, have had a detrimental impact on treatment facilities & gynecological clinics.

For instance, in low- and middle-income countries there has been a decline in the usage of long- and short-acting reversible contraceptives. Strategic initiatives undertaken by key players, such as collaborations, agreements, and partnerships, for the development and commercialization of products are anticipated to drive market growth. For instance, in October 2021, Richter and Hikma signed an exclusive licensing agreement to commercialize denosumab, comprising biosimilar of Xgeva and Prolia in the U.S. Moreover, the growing competition from generic drugs increases the pricing pressure after patent expiration, which is anticipated to impede market growth.

For instance, after the patent expiry, the revenue of Forteo declined by 23% between 2020 and 2021. North America dominated the global market in 2021 owing to favorable reimbursement policies, the presence of key market players, supportive government regulations, approval & commercialization of products, and high usage of contraceptives among women. The Asia Pacific region is expected to grow at the fastest CAGR during the forecast period due to rising government spending on women's health. For instance, the Australian Government announced an investment of USD 333 million to support health services and support.

Women's Health Market Report Highlights:

  • The contraceptives segment held the highest revenue share of more than 35.07% of the global revenue in 2024, spurred by rising awareness of family planning and ongoing technological advancements in contraceptive methods.
  • Hormonal therapies segment led the market in 2024 and is expected to grow at fastest growth rate over the forecast period.
  • The others (below 50 years) segment dominated the market in 2024 and is expected to sustain the position for the forecast period. Women aged below 50 years are more likely to face issues associated with fertility, such as endometriosis, hormonal infertility, and polycystic ovary syndrome.
  • The North America women's health market dominated the global market with a share of 43.04% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Age
    • 1.2.3. Regional scope
    • 1.2.4. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application outlook
    • 2.2.2. Drug class outlook
    • 2.2.3. Age outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Women's Health Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising incidence of target diseases
      • 3.2.1.2. Increasing initiatives by government and various organizations
      • 3.2.1.3. Rising publicly funded family planning services
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of major drugs
      • 3.2.2.2. Lawsuits related to products
      • 3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices
  • 3.3. Women's Health Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis

Chapter 4. Women's Health Market: Application Estimates & Trend Analysis

  • 4.1. Application Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Women's Health Market by Application Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Hormonal infertility
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Contraceptives
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Postmenopausal osteoporosis
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Endometriosis & uterine fibroids
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Menopause
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.6. Polycystic ovary syndrome (PCOS)
      • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Women's Health Market: Drug Class Estimates & Trend Analysis

  • 5.1. Drug Class Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Women's Health Market by Drug Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Hormonal Therapies
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Bone Health Agents
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Fertility Agents
      • 5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. GnRH Modulators
      • 5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.5. Pain and Symptom Management
      • 5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.6. Metabolic Agents
      • 5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.7. Others
      • 5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Women's Health Market: Age Estimates & Trend Analysis

  • 6.1. Age Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Women's Health Market by Age Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. 50 years and above
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.2. Postmenopausal osteoporosis
        • 6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.3. Endometriosis & uterine fibroids
        • 6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.4. Menopause
        • 6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 6.4.1.5. Others
        • 6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Others
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Women's Health Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Regulatory framework/ reimbursement structure
      • 7.6.6.3. Competitive scenario
      • 7.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Regulatory framework/ reimbursement structure
      • 7.6.7.3. Competitive scenario
      • 7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Regulatory framework/ reimbursement structure
      • 7.6.8.3. Competitive scenario
      • 7.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Regulatory framework/ reimbursement structure
      • 7.7.5.3. Competitive scenario
      • 7.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Regulatory framework/ reimbursement structure
      • 7.7.6.3. Competitive scenario
      • 7.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Argentina
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Regulatory framework/ reimbursement structure
      • 7.9.1.3. Competitive scenario
      • 7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Regulatory framework/ reimbursement structure
      • 7.9.2.3. Competitive scenario
      • 7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Regulatory framework/ reimbursement structure
      • 7.9.3.3. Competitive scenario
      • 7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Regulatory framework/ reimbursement structure
      • 7.9.4.3. Competitive scenario
      • 7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. AbbVie, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Bayer AG
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Pfizer, Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Teva Pharmaceutical Industries Ltd.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Agile Therapeutics
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Amgen, Inc.
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Apothecus Pharmaceutical Corp.
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Blairex Laboratories, Inc.
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Ferring B.V.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives